Order Article Reprints

Minarik J, Radocha J, Jungova A, Straub J, Jelinek T, Pika T, Pour L, Pavlicek P, Harvanova L, Pospisilova L, et al. Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy. Cancers. 2022; 14(20):5165. https://doi.org/10.3390/cancers14205165

Minarik, Jiri, Jakub Radocha, Alexandra Jungova, Jan Straub, Tomas Jelinek, Tomas Pika, Ludek Pour, Petr Pavlicek, Lubica Harvanova, Lenka Pospisilova, and et al. 2022. "Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy" Cancers 14, no. 20: 5165. https://doi.org/10.3390/cancers14205165

Minarik, J., Radocha, J., Jungova, A., Straub, J., Jelinek, T., Pika, T., Pour, L., Pavlicek, P., Harvanova, L., Pospisilova, L., Krhovska, P., Novakova, D., Jindra, P., Spicka, I., Plonkova, H., Stork, M., Bacovsky, J., Maisnar, V., & Hajek, R. (2022). Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy. Cancers, 14(20), 5165. https://doi.org/10.3390/cancers14205165